Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
University of Pittsburgh
Bristol-Myers Squibb
Bristol-Myers Squibb
Celgene
National Cancer Institute (NCI)
Bristol-Myers Squibb
Bristol-Myers Squibb